Is one month treatment with dabigatran before cardioversion of atrial fibrillation sufficient to prevent thromboembolism?

Anna-Karin Johansson; Tord Juhlin; Johan Engdahl; Stefan Lind; Kristina Hagwall; Cecilia Rorsman; Emöke Fodor; Anna Alenholt; Astrid Paul Nordin; Mårten Rosenqvist; Mats Frick

doi:10.1093/europace/euv123

Is one month treatment with dabigatran before cardioversion of atrial fibrillation sufficient to prevent thromboembolism?

Anna-Karin Johansson, Tord Juhlin, Johan Engdahl, Stefan Lind, Kristina Hagwall, Cecilia Rorsman, Emöke Fodor, Anna Alenholt, Astrid Paul Nordin, Mårten Rosenqvist, Mats Frick

Research output: Contribution to journal › Article › peer-review

Abstract

The use of direct oral anticoagulants (DOACs) in patients undergoing elective direct current (DC) cardioversion of non-acute atrial fibrillation (AF) can potentially shorten the time from initiation of anticoagulation treatment to cardioversion, compared with warfarin. The safety of this strategy needs to be investigated. Data from subgroup analysis from clinical trials with DOAC do not clarify whether 4-week treatment with DOAC is sufficient to prevent thromboembolism (TE) after cardioversion. The aim of this retrospective study was to assess the incidence of TE in anticoagulant naive patients converted after one month's pre-treatment with dabigatran.

Original language	English
Pages (from-to)	1514-1517
Journal	Europace
Volume	17
Issue number	10
DOIs	https://doi.org/10.1093/europace/euv123
Publication status	Published - 2015

Subject classification (UKÄ)

Cardiac and Cardiovascular Systems

Access to Document

10.1093/europace/euv123

http://www.ncbi.nlm.nih.gov/pubmed/26017466?dopt=Abstract

Cite this

@article{ad7a7b82daf445f988e88431f559cf3d,

title = "Is one month treatment with dabigatran before cardioversion of atrial fibrillation sufficient to prevent thromboembolism?",

abstract = "The use of direct oral anticoagulants (DOACs) in patients undergoing elective direct current (DC) cardioversion of non-acute atrial fibrillation (AF) can potentially shorten the time from initiation of anticoagulation treatment to cardioversion, compared with warfarin. The safety of this strategy needs to be investigated. Data from subgroup analysis from clinical trials with DOAC do not clarify whether 4-week treatment with DOAC is sufficient to prevent thromboembolism (TE) after cardioversion. The aim of this retrospective study was to assess the incidence of TE in anticoagulant naive patients converted after one month's pre-treatment with dabigatran.",

author = "Anna-Karin Johansson and Tord Juhlin and Johan Engdahl and Stefan Lind and Kristina Hagwall and Cecilia Rorsman and Em{\"o}ke Fodor and Anna Alenholt and {Paul Nordin}, Astrid and M{\aa}rten Rosenqvist and Mats Frick",

year = "2015",

doi = "10.1093/europace/euv123",

language = "English",

volume = "17",

pages = "1514--1517",

journal = "Europace",

issn = "1532-2092",